Human LIGHT Protein, Fc Tag (LIT-H5269) is expressed from human 293 cells (HEK293). It contains AA Asp 74 - Val 240 (Accession # O43557-1) trimer Design.
Predicted N-terminus: Pro
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 82.6 kDa. The protein migrates as 116 kDa under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>90% as determined by SDS-PAGE.
>90% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 150 mM NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human LIGHT Protein, Fc Tag on SDS-PAGE under non-reducing (NR) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
The purity of Human LIGHT Protein, Fc Tag (Cat. No. LIT-H5269) is more than 90% in HP-SEC, and the molecular weight of this protein is around 180-200 kDa verified by SEC-MALS.
Immobilized Human HVEM, His Tag (Cat. No. HVM-H52E9) at 5 μg/mL (100 μL/well) can bind Human LIGHT Protein, Fc Tag (Cat. No. LIT-H5269) with a linear range of 0.2-4 ng/mL (QC tested).
活性（Bioactivity）-Cell based assay
Human LIGHT Protein, Fc Tag (Cat. No. LIT-H5269) induced cytotoxicity in HT-29 cells. The ED50 for this effect is 1.29-2.38 ng/mL (Routinely tested).
Tumor necrosis factor ligand superfamily member 14(LIGHT) is a tumor necrosis factor (TNF) superfamily ligand that regulates T cell immune responses by signaling through the herpes virus entry mediator (HVEM) and the lymphotoxin beta receptor (LTbetaR). LIGHT has emerged as a potent initiator of T cell co-stimulation signals effecting CTL-mediated tumor rejection, allograft rejection and graft versus host disease. Constitutive expression of LIGHT leads to tissue destruction and autoimmune-like disease syndromes.